Investigational drug for amyotrophic lateral sclerosis
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests an investigational drug (FHND1002) for people with ALS to see if it can slow down the disease. It's for people with ALS who are in the early to moderate stages, have good breathing, and have been recently diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of ALS (Lou Gehrig's disease) that fits certain standard categories (definite, probable, etc.).
- Your ALS symptoms have been progressing at a certain rate (at least half a point per month on a standard scale).
- Your breathing is fairly strong: a breathing test shows at least 70% of expected, and you do not use a BiPAP machine.
- Your ALS started within the last 2 years.
- You have a decent level of daily functioning (a score of 30 or more on the ALS rating scale), and you can swallow well enough.
- Your weight is within a healthy range (BMI of 18.5 or higher).
- You have not had spinal surgery in the past 3 months and do not have other major health problems (like severe heart, liver, or kidney disease).
- If you are a woman who can get pregnant, you are not pregnant and agree to use effective birth control during the study and for 3 months after.
- You are willing and able to understand and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called FHND1002 in healthy adults aged 18 to 45. The goal is to check its safety, how well the body tolerates it, and how it is processed. It is one of the first tests in humans.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This trial tests an experimental oral medication called usnoflast for people with ALS. It aims to see if the drug can slow the disease's progression.
This trial tests whether FB1006 is safe and works better than usual care for treating amyotrophic lateral sclerosis (ALS). It focuses on people with relatively early ALS and good breathing function.
This trial tests whether a new medicine, made of tiny capsules containing a protein called nerve growth factor, can help people with ALS. It aims to see if the treatment can slow the disease and improve symptoms.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.